MAGI3-AKT3 fusion in breast cancer amended.

The article discusses a study on the frequency of MAGI3-AKT3 fusion in 236 triple-negative breast cancers (TNBCs) represented in high-density microarrays. TNBC constitutes majority of breast carcinomas and notes that TNBC patients have poor response to conventional breast cancer therapies and experience poor survival. It confirms that MAGI3-AKT3 fusion is not a recurrent event in triple-negative breast cancer that should be acknowledged prior to evaluating targeted therapies in clinical trials.